Abstract
Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital/Brown University, interprets data presented at the 2022 ASCO Annual Meeting on rucaparib maintenance in advanced ovarian cancer, single-agent trabectedin in BRCA-positive ovarian cancer, tisotumab vedotin and pembrolizumab in cervical cancer, and patient selection for bevacizumab use in ovarian cancer.
